Adverse Event Initiatives Aim For Better Data, Easier Reporting
This article was originally published in The Silver Sheet
Executive Summary
DEVICE ADVERSE EVENT REPORTING is gradually becoming less burdensome and more standardized as the result of initiatives at FDA and internationally. The MedSun program for a small subset of hospitals is well on its way toward eventually replacing universal user reporting of adverse events, with FDA officials saying the system is providing high quality information that can help manufacturers better understand problems that health care practitioners encounter with their products. Meanwhile, the Global Harmonization Task Force anticipates greater ease for industry in reporting adverse events to international regulatory bodies under its comprehensive reporting guidance, now nearly complete. National regulatory authorities, in turn, will find their job of sharing event data with one another simpler under a new coding system developed by ISO Technical Committee 210
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.